Drugs / LTI-03
LTI-03
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05954988 | Jul 2023 → Sep 2024 | idiopathic pulmonary fibrosis | Rein Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT04233814 | Jan 2020 → Dec 2021 | idiopathic pulmonary fibrosis | Rein Therapeutics | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06968845 | Feb 2026 → Sep 2027 expected | idiopathic pulmonary fibrosis | Rein Therapeutics | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LTI-03 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05954988 ↗ |
| Known as | Csp-7 | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068584 ↗ |
| Known as | Phe-thr-thr-phe-thr-val-thr | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068584 ↗ |
| Modality | Peptide | “LTI-03, a Caveolin-1 scaffold protein-derived 7-amino acid peptide to be administered as a dry powder by inhalation through a dry powder inhaler.” NCT04233814 ↗ |
| Route | Inhaled | “inhaled LTI-03” NCT04233814 ↗ |